

In the Claims

Prior to calculating the filing fees, please make the following amendments in the claims, without prejudice to filing future continuing applications.

Please Cancel Claims 1 - 10 (inclusive), 20, 21, 24-35 (inclusive), 37 and 38, without prejudice to future continuing applications.

Please Substitute the following Claims 11-19, 22-23 and 36, without prejudice to future continuing applications, for the Claims 11-19, 22-23 and 36 as originally filed, prior to calculating the filing fee.

A mark-up of the claims showing the changes made is attached hereto.

11. (AMENDED) An isolated DNA which comprises a DNA having a nucleotide sequence coding for an ependymin-like protein having an amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, or a substantial equivalent thereto, or a salt thereof.

12. (AMENDED) The isolated DNA according to claim 11, which comprises a nucleotide sequence represented by SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20.

13. (AMENDED) An isolated DNA which comprises a DNA having a nucleotide sequence coding for a protein having an amino acid sequence represented by SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:13, or a substantial equivalent thereto.

14. (AMENDED) The isolated DNA according to claim 13 which comprises a nucleotide sequence represented by SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO: 30.

15. (AMENDED) An isolated DNA which comprises a DNA having a nucleotide sequence coding for a signal peptide comprising an amino acid sequence represented by SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 or SEQ ID NO:17, or a substantial equivalent thereto.

16. (AMENDED) The isolated DNA according to claim 15, which comprises a nucleotide sequence represented by SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 or SEQ ID NO:34.

17. (AMENDED) An expressible recombinant vector comprising the DNA according to claim 11.

18. (AMENDED) A host cell which is transformed with the recombinant vector of claim 17.

19. (AMENDED) A method for producing an ependymin-like protein having an amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, or a substantial equivalent thereto, or a salt thereof, which comprises cultivating the host cell according to claim 18 under conditions and for sufficient time suitable to express and accumulate said protein, and collecting the same.

22. (AMENDED) A pharmaceutical composition which comprises the DNA according to claim 11 and a pharmaceutically acceptable carrier, excipient or diluent.

23. (AMENDED) A method for making a pharmaceutical composition which is a therapeutic or prophylactic agent for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration said method comprising combining a therapeutic amount of the DNA of Claim 11 with pharmaceutically acceptable carrier, excipient or diluent.

36. (AMENDED) A method for treating or preventing Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia or cerebellar degeneration in a mammal which comprises administering an effective amount of the DNA according to claim 11 or a salt thereof to said mammal.